Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ephedrine sulfate - Exela Sterile Medicines

Next Previous
Drug Profile

Ephedrine sulfate - Exela Sterile Medicines

Alternative Names: Akovaz; Ephedrine sulfate; UMD 3 - Avadel Pharmaceuticals; UMD#3 - Avadel Pharmaceuticals; Unapproved marketed drug 3 - Avadel Pharmaceuticals; Unapproved marketed drug#3 - Avadel Pharmaceuticals; Undisclosed drug#3 - Avadel Pharmaceuticals; Éclat #3

Latest Information Update: 17 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eclat Pharmaceuticals
  • Developer Avadel Pharmaceuticals
  • Class Analgesics; Antihypotensives; Decongestants; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Beta adrenergic receptor agonists; Central nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypotension

Most Recent Events

  • 12 Feb 2026 Avadel Pharmaceuticals has been acquired by Alkermes plc
  • 01 Jul 2020 Exela Sterile Medicines acquires ephedrine sulfate from Avadel Pharmaceuticals
  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top